My article in December's PharmaTimes reviewing the year's M&A in the Pharma and Life Science sector. With macro drivers boosting the sector and a range of attractive themes driving interest, M&A has remained buoyant, both at the large cap and mid market level.
Review of the Year: Pharma M&A shows its staying power With macro drivers boosting the sector and a range of attractive themes driving interest, M&A in the industry remains buoyant Conditions have been ripe for M&A in the pharmaceutical sector in 2017. Low interest rates have provided cheap capital for both financial and trade buyers, while acting as a disincentive to keep large cash balances on reserve; the devaluation of the pound has heightened the attractions of the UK for international investors; and economic uncertainty has boosted the defensive pharma sector’s appeal.
